共 50 条
Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors
被引:75
|作者:
Lang, P
Bader, P
Schumm, M
Feuchtinger, T
Einsele, H
Führer, M
Weinstock, C
Handgretinger, R
Kuci, S
Martin, D
Niethammer, D
Greil, J
机构:
[1] Univ Tubingen, Univ Childrens Hosp, Dept Pediat Oncol, D-72076 Tubingen, Germany
[2] Univ Tubingen, Dept Internal Med, Tubingen, Germany
[3] Univ Munich, Childrens Univ Hosp, Munich, Germany
[4] Univ Tubingen, Dept Transfus Med, Tubingen, Germany
[5] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
关键词:
stem cell transplantation;
alternative donors;
CD34(+) selection;
CD133(+)-selection;
haploidentical;
D O I:
10.1046/j.1365-2141.2003.04747.x
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Positive selected haematopoietic stem cells are increasingly used for allogeneic transplantation with the CD34 antigen employed in most separation techniques. However, the recently described pentaspan molecule CD133 appears to be a marker of more primitive haematopoietic progenitors. Here we report our experience with a new CD133-based selection method in 10 paediatric patients with matched unrelated (n = 2) or mismatched-related donors (n = 8). These patients received a combination of stem cells (median = 29.3 x 10(6)/kg), selected with either anti-CD34 or anti-CD133 coated microbeads. The proportion of CD133(+) selected cells was gradually increased from patient to patient from 10% to 100%. Comparison of CD133(+) and CD34(+) separation procedures revealed similar purity and recovery of target populations but a lower depletion of T cells by CD133(+) selection (3.7 log vs. 4.1 log, P < 0.001). Both separation procedures produced >90% CD34(+)/CD133(+) double positive target cells. Engraftment occurred in all patients (sustained primary, n = 8; after reconditioning, n = 2). No primary acute graft versus host disease (GvHD) greater than or equal to grade II or chronic GvHD was observed. The patients showed a rapid platelet recovery (median time to independence from substitution = 13.5 d), whereas T cell regeneration was variable. Five patients are alive with a median follow-up of 10 months. Our data demonstrates the feasibility of CD133(+) selection for transplantation from alternative donors and encourages further trials with total CD133(+) separated grafts.
引用
收藏
页码:72 / 79
页数:8
相关论文